Cervical cancer vaccines: Emerging concepts and developments

Journal of Cellular Physiology

Volumn 186, Issue 2, 2001, Pages 169-182

  Da Silva, Diane M ^a   Eiben, Gretchen L ^a   Fausch, Steven C ^a   Wakabayashi, Mark T ^a   Rudolf, Michael P ^a   Velders, Markwin P ^a   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; VACCINIA VACCINE; VIRUS DNA; VIRUS VECTOR;

ANIMAL MODEL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONDYLOMA; DENDRITIC CELL; FEMALE; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION; VIRUS INFECTION; WART VIRUS;

EID: 0035149837     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200102)186:2<169::AID-JCP1023>3.0.CO;2-H     Document Type: Review

References (165)

1. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope
2. A comparison of gene transfer methods in human dendritic cells
3. Dendritic cells: Development, function and potential use of cancer immunotherapy
4. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions
5. Progress in the development of human papillomavirus vaccines for HPV-11 and HPV-16/18 and mapping of a critical neutralizing epitope
6. Identification of H-2Kb binding and immunogenic peptides from human papillomavirus tumour antigens E6 and E7
7. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity
8. Human papillomavirus in the immunocompromised
9. Enhancing immune responses using suicidal DNA vaccines
10. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse
11. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
12. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
13. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective
14. Construction and characterization of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer
15. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection
16. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16
17. Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine
18. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs
19. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
20. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines
21. Antigen specific immunotherapy for human papillomavirus type 16 E7-expressing tumors grown in the liver
22. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen
23. Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16
24. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
25. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16
26. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of antigen gene to a Mycobacterium tuberculosis heat shock protein 70 gene
27. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies
28. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
29. Immunotherapy of a human papillomavirus (HPV) type 16 E7expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7
30. Immunological events in regressing genital warts
31. Identification of T- and B-cell epitopes of the E7 protein of human papillomavirus type 16
32. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells
33. Papillomavirus virus-like particles as anticancer vaccines
34. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles
35. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells
36. Vaginal immunization of Cynomolgus monkeys with Streptococcus gordonii expressing HIV-1 and HPV 16 antigens
37. High efficiency adenovirus-mediated gene transfer to human dendritic cells
38. A polyepitope DNA vaccine encoding HLA-restricted CTL epitopes of HPV16 E7 for the outbred human population
39. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
40. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles
41. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product
42. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes
43. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
44. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
45. Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16
46. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumour immune responses in vitro and in vivo
47. A dose-ranging study of the safety and immunogenicity profiles of an HPV 11 L1 VLP candidate vaccine in young healthy women
48. Immune response to human papillomavirus type 16 E6 gene in a live vaccinia vector
49. Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection
50. HPV16 E7-based protein immunization induces long-term protective and therapeutic anti-tumor immunity in C57BL/6 mice
51. Clinical and pathological response in a phase II trial (SGN-00101-09902) of HspE7 in high grade anal dysplasia
52. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model
53. Three dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids
54. Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies
55. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity
56. Protection of rabbits from viral challenge by gene gun-based intracutaneous vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6, and E7 genes
57. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX
58. A safety and immunogenicity trial of a human papillomavirus type 16 L1 virus-like particle vaccine in healthy young adult human volunteers
59. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes
60. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16
61. HPV16 E7 recombinant Kunjin Flavivirus replicon as a vaccine for E7-expressing tumour
62. Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma
63. Genetically modified tumor cell vaccines
64. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo
65. Enhancement of DNA vaccine potency by linkage of antigen gene to a Flt3-ligand gene
66. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins
67. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein
68. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
69. Single dose subcutaneous administration of HspE7 induced lymphoproliferative responses to HPV 16 E7 in healthy volunteers
70. Protection against lethal Sendal virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide
71. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified using the processing-deficient human cell line T2
72. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins
73. In vitro construction of pseudovirions of human papillomavirus type 16: Incorporation of plasmid DNA into reassembled L1/L2 capsids
74. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
75. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles
76. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization
77. A phase II HPV16 E6 and E7 peptides vaccination in patients with advanced cervical cancer
78. Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein
79. Induction of an antibody response in mice against human papillomavirus (HPV) type 16 after immunization With HPV recombinant Salmonella strains
80. Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors
81. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
82. DNA vaccines
83. Genital papillomavirus infection and cervical dysplasia-opportunistic complications of HIV infection
84. Acute activation of dendritic cells by papillomavirus-like particles
85. Treatment of established tumors with a novel vaccine that enhances major histocempatibility class II presentation of tumor antigen
86. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
87. Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes
88. Immunisation of mice using Salmonella typhimurium expressing human papillomavirus type 16 E7 epitopes inserted into hepatitis B virus core antigen
89. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast
90. Human papillomavirus-specific immunity induced following immunization with recombinant Mycobacterium bovis bacille calmette-guérin (BCG) expressing HPV-16 L1 protein
91. Human immunodeficiency virus infection and cervical neoplasia
92. A recombinant human papillomavirus (HPV) type 16 L1-vaccinia virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles
93. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity
94. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7
95. Circumvention of vecto-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: Implications for gene therapy
96. A phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
97. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human karatinocytes
98. + T-lymphocyte responses using a human papillomavirus-16 E6/E7 fusion protein and autologous dendritic cells
99. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice
100. Mucosal but not parenteral immunization with purified human papillomavirus type 16 virus-like particles induces neutralizing titers of antibodies throughout the estrous cycle of mice
101. Behavior of mild cervical dysplasia during long-term follow-up
102. Cervical tumour lysate as a source of antigen for dendritic cell (DC) based immunotherapy of cervical cancer
103. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response
104. Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III
105. Pre-clinical safety and immunogenicity of TA-CIN: A recombinant HPV16 L2E7E6 fusion protein vaccine for the treatment of cervical intraepithelial neoplasia
106. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor
107. RNA virus vectors: Where are we and where do we need to go?
108. Estimates of the worldwide incidence of 25 major cancers in 1990
109. HPV16 forms a single serotype: Neutralization of variant HPV16 pseudovirions by human sera from HPV16 VLP vaccinees
110. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway
111. Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA
112. Estimates of the worldwide mortality from 25 cancers in 1990
113. A randomized, double-blind, placebo-controlled trial of the immunogenicity and reactogenicity of a novel HPV 16 vaccine: Preliminary results
114. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides
115. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A*0201-restricted E7-encoded epitope
116. Detection oft helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
117. Mucosal vaccination with a recombinant Salmonella/HPV16 VLP strain or purified HPV16 VLP induces antitumor immunity in mice
118. Role of cell-mediated immunity in spontaneous regression of plane warts
119. Proliferating dendritic cell progenitors in human blood
120. Assembly of human papillomavirus type 16 pseudovirions in Saccharomyces cerevisiae
121. Human papillomavirus infections in a group of renal transplant recipients
122. Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles
123. Human T cell responses to HLA-A restricted high binding affinity peptides of HPV-18 proteins E6 and E7
124. Human dendritic cells are activated by HPV-16 VLPs and induce epitope specific human T cell responses in vitro
125. + lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer
126. Development, characterization and distribution of adoptively transferred peripheral blood lymphocytes primed by human papillomavirus 18 E7-pulsed autologous dendritic cells in a patient with metastatic adenocarcinoma of the uterine cervix
127. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: Induction of cytotoxic T cells and specific tumor protection
128. Peptide-induced antiviral protection by cytotoxic T cells
129. Human papillomavirus type 16 E7 DNA vaccine: Mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and antitumor activity
130. Papillomavirus pseudovirions induce a stronger CTL response than a DNA vaccine
131. A murine model for the effects of pelvic radiation and cisplatinum chemotherapy on human papillomavirus vaccine efficacy
132. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs
133. Infectious human papillomavirus type 18 pseudovirions
134. Induction of cytotoxic T lymphocytes with peptides in vitro: Identification of candidate T-cell epitopes in human papilloma virus
135. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitepe of human papilomavirus type 16 E7
136. Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: Identification of T cell determinants, HLA-DR restriction and virus type specificity
137. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
138. Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts
139. Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: Implications for cervical cancer immunotherapy
140. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors
141. Peptide vaccination can lead to enhance tumor growth through specific T-cell tolerance induction
142. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
143. In vitro gene transfer using human papillomavirus-like particles
144. Genetically modified bone marrow-derived dendritic cells expressing tumorassociated viral or "self" antigens induce antitumor immunity in vivo
145. Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice
146. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
147. Identification of peptides for immunotherapy of cancer. It is still worth the effort
148. An epitope based DNA vaccine against HPV16 prevents tumor formation and induces regression of established tumors
149. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif
150. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: Consequences for the phenotype and E6-53 and E7-pRB interactions
151. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
152. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific antitumor immunity
153. Enhancement of Semliki Forest virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartment
154. Association of human papillomavirus types 16 and 18 E6 proteins with p53
155. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papiilomavirus type 16
156. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier
157. Cancer therapy using a selfreplicating RNA vaccine
158. Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors
159. Antigen-specific tumor vaccines. Development and characterization of recombinant adeno viruses encoding MART1 or gp100 for cancer therapy
160. HPV6b virus-like particles are potent immunogens without adjuvant in man
161. Both immunization with protein and recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papillomavirus 16 in H-2d mice
162. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
163. Papillomavirus infections - A major cause of human cancers